

ITGAV Specific Recomb™ Antibody (V3S-1223-FY24), Human IgG1, kappa

Cat. No.: V3S-1223-FY24

Summary

Description	CNTO95 is a human IgG1, kappa monoclonal antibody that inhibits the migration of human melanoma and endothelial cells. CNTO95 has been demonstrated to bind to all subunits of the integrins that contain alpha V, except those containing $\alpha 5$ or $\alpha 1b$ heterodimers. It blocks the binding of both $\alpha V\beta 3$ and $\alpha V\beta 5$ to vitronectin in cell-based assays.
Clonality	Monoclonal
Host Species	Human
Target Species	Human
Affinity	$K_D = 0.21 \pm 0.133$ nM ($\alpha V\beta 3$), $K_D = 25 \pm 10.4$ pM ($\alpha V\beta 5$).
Isotype	Human IgG1, kappa
Isotype Control	C67002
Secondary Antibody	C23324

Property

Expression Species	HEK293F or CHO
Purity	>95%, determined by SDS-PAGE and SEC-HPLC
Endotoxin	<1 EU/mg
Purification	Protein A affinity purified
Sterility	0.2 μ M filtered
Formulation	PBS, pH 7.4
Preservation	No preservatives
Stabilizer	No stabilizers
Storage	Store at 4°C within a week. For longer storage, aliquot and store at -20°C.

Applications

For lab research use only, not for diagnostic, therapeutic or any *in vivo* human use.

Application	ELISA; Block
Application Notes	ELISA: 0.7 µg/mL

Target

Target	ITGAV
Alternative Name	ITGAV; CD51; MSK8; VNRA; VTNR; integrin subunit alpha V
Gene ID	3685
UniProt	P06756
Introduction	ITGAV encodes integrin alpha chain V. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. Alpha V undergoes post-translational cleavage to yield disulfide-linked heavy and light chains, that combine with multiple integrin beta chains to form different integrins.
Related pathway	Apoptotic signaling pathway
Research Area	Cardiovascular; Signal Pathway
Related Disease	Cardiovascular disease, Immune related disease, Malignant disease

For lab research use only, not for diagnostic, therapeutic or any *in vivo* human use.